Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

The deal sees rights to JNJ-3989 (also known as ARO-HBV) transfer from J&J’s Janssen pharmaceuticals unit to GSK in return for around $1 billion in upfront and potential milestone-based payments.

Janssen hopes to use the technology to silence the genetic material that allows hepatitis B to become established in the body, gaining exclusive worldwide rights to develop and market ARO-HBV ...